Although general medical histories were collected from all subjects at study start, information relating to such potentially predisposing comorbid conditions was not collected systematically. Therefore, we were unable to determine from the available data if the overall baseline level for certain risk factors was similar between groups. Similarly, we could not conclusively investigate LY2835219 in vitro whether patients with particular baseline characteristics might be at increased risk to develop certain infections with denosumab. In denosumab-treated subjects, white blood cell counts remained stable over time
and similar to placebo. Serious adverse events of infections that occurred with denosumab had heterogeneous etiology, with no clear clinical www.selleckchem.com/products/azd8186.html pattern to suggest a relationship to time or duration of exposure to denosumab. In aggregate, these findings are consistent with the evidence that suggests there is a redundancy of function in the adult immune system, with RANKL playing a minimal role [34] and inhibition of RANKL having little or no adverse effect in this regard. Denosumab safety has been evaluated Selleckchem GANT61 across the clinical development program. In a small phase 3 trial comparing denosumab
and placebo in a younger population (mean age, 59 years) of 332 postmenopausal women with low bone mass, subjects treated with denosumab had significantly more serious adverse events of infections that were associated with hospitalization [7]. The serious adverse events of infections were common infections for the population studied
and were treated successfully with standard antibiotics; no pattern MycoClean Mycoplasma Removal Kit was observed in the type of body systems affected. No significantly increased risk of serious adverse events of infections was observed in any other phase 2 and phase 3 clinical trials of denosumab compared with placebo or alendronate in postmenopausal women with low bone mass [7, 35–37]. Denosumab has also been studied in other disease populations. No increased risk of infection with denosumab (60 or 180 mg Q6M) was noted in clinical trials of patients with rheumatoid arthritis receiving methotrexate or in patients receiving hormone ablation therapy for breast or prostate cancer (denosumab 60 mg Q6M) [38–40]. Similarly, no increased risk of infection was observed for a higher dose of denosumab (120 mg every 4 weeks) compared with zoledronic acid in several large trials in patients with advanced cancer or multiple myeloma and bone metastases [41–43]. In this analysis, we endeavored to develop a better understanding of the effects of RANKL inhibition with denosumab by evaluating infectious events in postmenopausal women with osteoporosis participating in the phase 3 pivotal fracture trial.
Related posts:
- hiv-druginteractionsorg) (GPP]) There are few data to guide pre
- [10] Probiotics have in general been considered safe[11] Prebiot
- hiv-druginteractionsorg) (GPP]) There are few data to guide pre
- Similar results were found on comparing samples of healthy subjec
- AS-252424 ugh it is difficult to ascertain the exact